Such programs should cover medications listed on the Drug Enforcement Administration’s schedules 2, 3, 4, and 5, wrote Jeanmarie Perrone, M.D., of the University of Pennsylvania, and Lewis Nelson, M.D., of New York University, in an article published online in the New England Journal of Medicine May 30. The ideal monitoring program, they said, should include ease of access, standardized content, real-time updates, mandatory pharmacy reporting, interstate accessibility, confidentiality and security guarantees, and strictly monitored access for nonprescribers.
To read more about the complexities involved in prescribing pain medications, see Psychiatric News here.
(Image: Feng Yu/Shutterstock.com)